TITLE

FDA Panel Favors Xiaflex in Dupuytren's Disease

PUB. DATE
September 2009
SOURCE
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the support given by the U.S. Food and Drug Administration (FDA) panel on the use of Xiaflex developed by Auxilium Inc. in treating Dupuytren's disease. It states that the Arthritis Drugs Advisory Committee of FDA has voted for the approval of the drug which will be used as treatment of the disease. However, some members of the panel raised their concerns over the administration of the drug outside the clinical trial environment.
ACCESSION #
44369832

 

Related Articles

  • Despite Concerns, Panel Favors Auxilium's Xiaflex in Dupuytren's. Young, Donna // BioWorld Today;9/17/2009, Vol. 20 Issue 179, p1 

    The article reports on the decision by the Arthritis Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to approve the drug collagenase clostridium histolyticum branded as Xiaflex from Auxilium Inc. Xiaflex is designed to treat Dupuytren's disease, a progressive disease that...

  • Auxilium Shares Jump on Good FDA Xiaflex Review.  // Bioworld Week;9/21/2009, Vol. 17 Issue 38, p3 

    The article reports on the impact of the positive review given by the U.S. Food and Drug Administration (FDA) on the use of Xiaflex on the shares of Auxilium Inc. It states that the positive review of FDA has driven the investors to increase their shares in Auxilium. It adds that the...

  • Auxilium Raising $107M on Heels of Xiaflex Panel Win. Morrison, Trista // BioWorld Today;9/28/2009, Vol. 20 Issue 186, p1 

    The article reports on a 3 million share public offering issued by Auxilium Pharmaceuticals Inc. one week after a U.S. Food and Drug Administration (FDA) panel unanimously approved its Xiaflex for the treatment of Dupuytren's disease. The approval bid for Xiaflex is supported by 13 clinical...

  • FDA Expands Clinical Trial Disclosures. GOEDERT, JOSEPH // Health Data Management;Mar2012, Vol. 20 Issue 3, p14 

    The article reports that the U.S. Food and Drug Administration (FDA) will require research subjects in clinical trials to be informed of financial arrangements or prior misconduct of clinical investigators.

  • FDA finalizes CI debarment rule. McCarty, Mark // Medical Device Daily;5/3/2012, Vol. 16 Issue 86, p9 

    The article reports on a rule finalized by the U.S. Food and Drug Administration (FDA) governing clinical investigator (CI) debarment, preventing participation by CI in trials for any product rather than just trials within the product class for which the investigator was barred.

  • FDA APPROVES DULOXETINE HCI FOR THE MANAGEMENT OF FIBROMYALGIA.  // CNS Spectrums: The International Journal of Neuropsychiatric Med;Jul2008, Vol. 13 Issue 7, p552 

    The article reports that the Food and Drug Administration has approved duloxetine HCI for the management of fibromyalgia in the U.S. The approval was based on the results of two clinical trials representing 874 patients with fibromyalgia. According to the Brief Pain Inventory (BPI), in both...

  • New Drug Approved to Straighten Bent Fingers. B. G. // Arthritis Today;Jul/Aug2010, Vol. 24 Issue 4, p60 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Xiaflex to treat disabled and disconfigured hand condition called Dupuytren's contracture.

  • The FDA and the Declaration of Helsinki. Goodyear, Michael D. E.; Lemmens, Trudo; Sprumont, Dominique; Tangwa, Godfrey // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/16/2009, Vol. 338 Issue 7704, p1157 

    The article reflects on the impact of the declaration of the U.S. Food and Drug Administration (FDA) that clinical trials outside the country need not conform to the Declaration of Helsinki if used to support applications for registration of product in the U.S. He says that FDA's adoption of...

  • Paperless Clinical Trial Optimization-Thinking Outside the Box. Smyth, Michael // Applied Clinical Trials;Jul/Aug2013, Vol. 22 Issue 7/8, p12 

    The article focuses on the development of paperless clinical trials that can centralize the administrative burdens. It mentions that the U.S. Food and Drug Administration (FDA) have also realized the requirement of modernizing the clinical trials for efficiently performing clinical studies of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics